Applied genetics

North American Biobanks Market 2020: Alarm Monitoring Systems Segment is Expected to Show Better Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 21, 2020
Stem cells, Biotechnology, Medical Supplies, Oncology, Health, Diabetes, Medical devices, Genetics, Contents, Biological databases, Applied genetics, Biobank, Academic disciplines, Articles, Refrigerator, Cryogenics, Automation

The "North America Biobanks Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Biobanks Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • The cryogenic storage systems, freezers, refrigerators, and all other storage devices in a biobank require continuous monitoring of various processes.
  • Hence, with advancements in technology and the rising adoption of automated storage systems, there is high demand for automated alarm monitoring devices, which is expected to fuel the market growth.

NorthShore provides real time genomic decision support to 10,000 patients using the ActX Service

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, Medicine, Medical genetics, Clinical medicine, Medical tests, Alternatives to animal testing, Genetic testing, Genomics, Applied genetics, Genomic counseling

In 2016, they implemented ActX Genomic Decision Support inside Epic.

Key Points: 
  • In 2016, they implemented ActX Genomic Decision Support inside Epic.
  • NorthShore has taken an additional 10,000 patients through genetic testing as part of the DNA-10K initiative.
  • Our service helps physicians make better decisions about medical treatment, using a patient's genetic information to guide therapy.
  • The ActX Genomic Service offers proven, tightly integrated, real-time genomic decision support for medication orders and actionable genomic risks, a built in patient Genomic Profile, and the ability to fully customize content.

LL COOL J, Mario Lopez and Rob Lowe to Join Kathie Lee Gifford, Tori Kelly & Ancestry® this Memorial Day for Virtual “Parade of Heroes”

Retrieved on: 
Tuesday, May 19, 2020
Health, Online, Technology, Genetics, Consumer, Other Consumer, Other Technology, Entertainment, Applied genetics, Genealogy websites, Branches of biology, Genetics, Ancestry.com, Domain driven data mining, Academic disciplines, OMERS, Health, Online, Technology, Genetics, Consumer, Other Consumer, Other Technology, Entertainment, Applied genetics, Genealogy websites, Branches of biology, Genetics, Ancestry.com, Domain driven data mining, Academic disciplines, OMERS

Finding a personal connection is as simple as entering a grandparents name at Ancestry.com/WWII .

Key Points: 
  • Finding a personal connection is as simple as entering a grandparents name at Ancestry.com/WWII .
  • Ancestry, the global leader in family history and consumer genomics, empowers journeys of personal discovery to enrich lives.
  • With our unparalleled collection of 24 billion records and over 16 million people in our growing DNA network, customers can discover their family story and gain actionable insights about their health and wellness.
  • For over 30 years, weve built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing the most important information about themselves and their families.

CureDuchenne Applauds Pfizer’s Encouraging Data from Phase Ib Mini-Dystrophin Gene Therapy Trial for Duchenne Muscular Dystrophy

Retrieved on: 
Friday, May 15, 2020
Research, Genetics, Clinical trials, Philanthropy, Biotechnology, Managed care, Pharmaceutical, Health, Other Philanthropy, Science, Branches of biology, Biology, RTT, Genetics, Genetic engineering, Applied genetics, Biotechnology, Duchenne muscular dystrophy, Duchenne, Dystrophy, Muscular dystrophy, Gene therapy

CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects that have completed the 12 month Phase Ib clinical trial presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects that have completed the 12 month Phase Ib clinical trial presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
  • Pfizer is proud to be developing this potentially transformative therapy for the Duchenne muscular dystrophy community.
  • We are pleased to see such encouraging data from Phase Ib and to see Pfizer progress to planning a global Phase III gene therapy clinical trial for Duchenne muscular dystrophy.
  • CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne muscular dystrophy.

Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study

Retrieved on: 
Friday, May 15, 2020
Pharmaceutical, Health, Clinical trials, Muscular dystrophy, Branches of biology, Biology, Articles, RTT, Applied genetics, Biotechnology, Genetic engineering, Duchenne muscular dystrophy, DMD, Duchenne, Dystrophin, PF-06939926, Duchenne Muscular Dystrophy, Pfizer: Breakthroughs That Change Patients’ Lives

Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD).
  • Our program has the potential to be the first DMD gene therapy Phase 3 trial start using a commercial-scale manufacturing process.
  • Data presented at the ASGCT virtual meeting included results from the study of 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years).
  • The primary endpoint of the Phase 1b study is to assess the safety and tolerability of this investigational gene therapy in ambulatory boys with Duchenne muscular dystrophy through 12 months following treatment.

Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Retrieved on: 
Friday, May 15, 2020
Biotechnology, Health, Oncology, Clinical trials, Branches of biology, Biology, Genetics, Vaccination, Applied genetics, Biotechnology, Medical genetics, Genomics, Cancer vaccine, Viral vector, Vaccine, Cancer

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NECs Neoantigen Prediction System.
  • myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors.

The Non-viral Transfection Reagents and Systems Market is Projected to be Worth USD 1.4 Billion by 2030, Growing at a CAGR of 9.2%, Claims Roots Analysis

Retrieved on: 
Thursday, May 14, 2020
Branches of biology, Biology, Molecular biology, Life sciences, Gene delivery, Biotechnology, Applied genetics, Transfection

LONDON, May 14, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of " Non-Viral Transfection Reagents and Systems Market, 2020-2030 " report to its list of offerings.

Key Points: 
  • LONDON, May 14, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of " Non-Viral Transfection Reagents and Systems Market, 2020-2030 " report to its list of offerings.
  • The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.
  • To request a sample copy / brochure of this report, please visit this link
    Who are the leading players that offer non-viral transfection reagents and systems?
  • The USD 1.4 billion (by 2030) financial opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:

The Non-viral Transfection Reagents and Systems Market is Projected to be Worth USD 1.4 Billion by 2030, Growing at a CAGR of 9.2%, Claims Roots Analysis

Retrieved on: 
Thursday, May 14, 2020
Branches of biology, Biology, Molecular biology, Life sciences, Biotechnology, Gene delivery, Applied genetics, Transfection

The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.

Key Points: 
  • The growing demand for safe and effective genetically engineered ATMPs is likely to further propel the opportunity for non-viral transfection system developers.
  • Further, it is worth noting that close to 50% of these trials were initiated in the last five years alone.
  • To request a sample copy / brochure of this report, please visit this link
    Who are the leading players that offer non-viral transfection reagents and systems?
  • The USD 1.4 billion (by 2030) financial opportunity within the non-viral transfection reagents and systems market has been analyzed across the following segments:

uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting

Retrieved on: 
Thursday, May 14, 2020
Neurological disorders, Branches of biology, Organ systems, Rare diseases, Neurodegenerative disorders, Autosomal dominant disorders, Spinocerebellar ataxia, Applied genetics, Primate, Pre-clinical development, Machado–Joseph disease, Ataxia

The data are featured in presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • The data are featured in presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
  • uniQure is delivering a total of 22 data presentations at the meeting, which is taking place virtually from May 12 to May 15.
  • We are happy to share new preclinical data on our gene therapy candidates, as well as our innovations in technology and manufacturing.
  • The uniQure presentations in Spinocerebellar Ataxia type 3 (SCA3) show a continuation of strong proof-of-concept data in mice and other preclinical models, as well as encouraging new data in non-human primates (NHPs).

Wisdom Health Genetics Rolls Out Enhanced Dog DNA Tests

Retrieved on: 
Tuesday, May 12, 2020
Medicine, Branches of biology, Alternatives to animal testing, Genetic testing, Buccal swab, Clinical medicine, Applied genetics

VANCOUVER, Wash., May 12, 2020 /PRNewswire/ -- Wisdom Health Genetics , the world's leader in pet genetics and makers of the Wisdom Panel dog DNA tests, announced today the launch of two new and improved dog DNA tests: the Wisdom Panel Essential test and the Wisdom Panel Premium test.

Key Points: 
  • VANCOUVER, Wash., May 12, 2020 /PRNewswire/ -- Wisdom Health Genetics , the world's leader in pet genetics and makers of the Wisdom Panel dog DNA tests, announced today the launch of two new and improved dog DNA tests: the Wisdom Panel Essential test and the Wisdom Panel Premium test.
  • The Wisdom Panel Premium test provides all that the Wisdom Panel Essential version does, plus health analysis including 250+ health and trait tests.
  • Both Wisdom Panel tests are available now and require only a simple cheek swab to collect a dog's DNA.
  • Wisdom Panel dog DNA tests - backed by the Wisdom Health scientific research - can help pet parents plan better, care smarter, and love longer.